Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa

Trial Profile

A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Bermekimab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Adverse reactions
  • Sponsors XBiotech
  • Most Recent Events

    • 28 Jan 2019 According to an XBiotech media release, data will be presented at the 2019 American Academy of Dermatology (AAD) annual meeting.
    • 23 Jan 2019 According to a XBiotech media release, Dr. Alice Gottlieb, M.D., Ph.D., (Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY) is the the Chair of this study.
    • 23 Jan 2019 Results (n=42) presented in a XBiotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top